Clinical trials: Allogenic Disease
AML (Acute Myeloid Leukemia), BPDCN
CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults
The purpose of this phase I/II clinical trial is to test CARCIK-CD123/33 cells to treat patients with R/R AML/BPDCN, who have otherwise exhausted conventional treatment options.
- Trial name
- Dual CARCIK (NCT07877610)
- Testing
- CARCIK CD123/33 infusion
- Where
- 2 sites in Italy
- Volunteers
- 18 people
- Sponsor
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Hematologic Malignancies, Hematologic Disorders
Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients
This study reviews patients who received haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Some patients develop donor-specific antibodies (DSA), which can block engraftment and cause transplant failure.
- Conditions
- Hematologic Malignancies, Hematologic Disorders, Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Graft Failure
- Trial name
- PAIA-Haplo (NCT07200583)
- Testing
- Protein A immunoadsorption, Rituximab (optional, in some patients), Bortezomib (optional, in some patients)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ting YANG
Cytomegalovirus Infection
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
The purpose of this study was to evaluate the safety and efficacy of letermovir (LET) versus placebo when cytomegalovirus (CMV) prophylaxis was extended from 100 days to 200 days post-transplant in CMV seropositive participants…
- Trial name
- NCT03930615
- Testing
- Letermovir
- Where
- 32 sites in United States, France and 4 more
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Graft Versus Host Disease Grade II-IV, Allogeneic Stem Cell Transplant
Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease
The primary objective of this trial is as follows: To determine the pharmacokinetics of micafungin given twice weekly in patients at risk for developing an invasive fungal disease (patients who are being treated for acute or…
- Conditions
- Acute Graft Versus Host Disease Grade II-IV, Allogeneic Stem Cell Transplant, Acute Myeloid Leucaemia, Myelo Dysplastic Syndrome
- Trial name
- MATADOR (NCT02172768)
- Testing
- alternate dosing, daily dosing, micafungin
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Leukemia, Myelodysplastic Syndromes
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by…
- Trial name
- NCT00024050
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia
Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT
The purposes of the study are to determine the maximum tolerated dose (MTD) and effectiveness of Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion after an allogeneic hematopoietic…
- Trial name
- NCT05015426
- Testing
- Gamma Delta T-Cell Infusion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Leukemia, Myelodysplastic Syndrome
Pharmacokinetics of Anidulafungin (Ecalta ®) Intravenous Given to Patients at High Risk for Developing Invasive Fungal Disease
The purpose of this study is to study the pharmacokinetics of anidulafungin (Ecalta ®) given intravenously as antifungal prophylaxis to recipients of an allogeneic haematopoietic stem cell transplant following myeloablative…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Leukemia, Myeloid, Acute
- Trial name
- ANIDULAPK (NCT01249820)
- Testing
- anidulafungin 200 mg q48h, anidulafungin 300 mg q72h
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- Radboud University Medical Center
Hematologic Malignancies
Phase II Trial of Pentostatin and Targeted Busulfan
The objective of this trial is to determine whether a regimen of pentostatin and busulfan (IV) can facilitate engraftment of human leukocyte antigen (HLA) partially compatible siblings and unrelated donor transplants by using…
- Trial name
- Pento & tBU (NCT00496340)
- Testing
- Pentostatin, Busulfan, Rituximab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Hematological Malignancies
MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT
Allogeneic stem cell transplantation (allo-SCT) is a potent treatment, and sometimes the only curative treatment for aggressive hematological malignancies.
- Trial name
- PSCT19 (NCT02528682)
- Testing
- MiHA-loaded PD-L-silenced DC Vaccination
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Leukemia, Lymphocytic
Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults
This study is a multicenter trial of treatment for young ALL patients. All ALL patients will receive the same steroid pre-phase in order to evaluate sensitivity or resistance.
- Trial name
- NCT00327678
- Testing
- Rituximab, Imatinib Mesylate
- Where
- France
- Volunteers
- 1,080 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rectovaginal Fistula, Crohn Disease
Allogenic Stem Cells Derived From Lipoaspirates for the Treatment of Recto-vaginal Fistulas Associated to Crohn's Disease (ALOREVA)
The purpose of this study is to determine safety and efficacy of allogenic eASCs (expanded adult stem cells) for the treatment of recto-vaginal fistula in patients with Crohn´s disease.
- Trial name
- ALOREVA (NCT00999115)
- Testing
- Expanded allogenic adipose-derived adult stem cells
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz
CMV Infection, Hematopoietic Stem Cell Transplantation
Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China
In the 30 years of fighting CMV infection, the mortality rate among HSCT patients has significantly reduced. Now, the focus is on improving the prognosis of HSCT patients and preventing CMV infection.
- Trial name
- NCT05789615
- Testing
- Letermovir
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Bone Resorption, Dental Diseases
Allogeneic Bone Paste Versus Allogeneic Bone Powder
Autogenous bone graft has been considered the gold standard in Guided Bone Regeneration (GBR) technique used for bone augmentation.
- Trial name
- NCT04141215
- Testing
- BIOBank bone paste, BIOBank cortico-cancellous bone powder
- Where
- France
- Volunteers
- 86 people
- Sponsor
- Biobank
Perianal Fistula Due to Crohn's Disease
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
This is a double-blind, randomized, placebo-controlled, sequential cohort, ascending dose clinical trial to evaluate the safety and determine the efficacy of ascending doses of DB-3Q for the treatment of Perianal Fistulizing…
- Trial name
- NCT06918808
- Testing
- DB-3Q
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Direct Biologics, LLC
Focal Segmental Glomerulosclerosis
Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)
Idiopathic Focal Segmental Glumero Sclerosis (FSGS) is not very common but important manifestation of kidney disease. FSGS has poor prognosis among the patterns of Idiopathic Nephrotic Syndrome (INS).
- Trial name
- NCT02382874
- Testing
- Intravenous injection
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Royan Institute
ST Elevation Myocardial Infarction
Umbilical Cord Mesenchymal Stem Cell Improve Cardiac Function on ST-elevation Myocardial Infarction (STEMI) Patients
The goal of this clinical trial is to learn about the effectiveness of Umbilical Cord Mesenchymal Stem Cell (UC MSC) therapy in patients with STEMI against infarct myocardial size reduction and prevent the incidence of heart…
- Trial name
- NCT05935423
- Testing
- Umbilical Cord Mesenchymal Stem Cell transplantation
- Where
- Indonesia
- Volunteers
- 60 people
- Sponsor
- Universitas Indonesia
Lymphoma, Non-Hodgkin, Hodgkin Disease
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
For patients with lymphoma that recurs after chemotherapy, bone marrow transplantation using cells from a healthy donor represents potentially curative treatment.
- Trial name
- NCT01745354
- Testing
- SD-101, Local Radiation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Robert Lowsky
Allogeneic Stem Cell Transplantation
Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
The objective of this study is to assess the efficacy and safety of oral valganciclovir versus intravenous ganciclovir in patients following allogenic stem cell transplantation.
- Trial name
- CONVINCE (NCT01185223)
- Testing
- Valganciclovir, Ganciclovir
- Where
- 17 sites in Austria, Germany and 1 more
- Volunteers
- 212 people
- Sponsor
- Pierrel Research Europe GmbH
Diffuse Intrinsic Pontine Glioma
Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines
The purpose of this study is to asses safety of diffuse intrinsic pontine glioma (DIPG) treatment with autologous dendritic cells pulsed with lysated allegenic tumor lines Evaluate the nonspecific immune response generated in…
- Trial name
- NCT02840123
- Testing
- Autologous dendritic cells
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Fundació Sant Joan de Déu
Multiple Sclerosis
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for MS
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of multiple sclerosis
- Trial name
- NCT05003388
- Testing
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
- Where
- 2 sites in United States, Greece
- Volunteers
- 15 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.